Sunday, October 11, 2026

Indices

2 articles

SOXX Up 79% YTD as AI Semiconductor Supercycle Expands Beyond Data Centers

SOXX Up 79% YTD as AI Semiconductor Supercycle Expands Beyond Data Centers

The iShares Semiconductor ETF gained 79% year-to-date and 152% over one year as of June 5, 2026, with the 2x leveraged proxy adding 196% over the same window. The trade is broadening from hyperscaler hardware into edge AI, quantum computing, and satellite compute—extending the supercycle's runway. Geopolitical fracture and rising ASIC design costs are reshaping the competitive landscape but have not reversed the trend.

LM Salvado•
Semiconductor Index Hits Record High as AI Memory Shortage Triggers 3-4% Supply Gap Through 2026

Semiconductor Index Hits Record High as AI Memory Shortage Triggers 3-4% Supply Gap Through 2026

Semiconductor indices reached all-time highs despite a persistent 3-4% DRAM and NAND shortage through 2026, driven by Nvidia-led AI infrastructure demand. High-bandwidth memory requirements for AI workloads are straining manufacturing capacity, creating premium pricing opportunities for memory suppliers. Intel's 18A process and Micron's US fab expansions aim to capture AI-era supply constraints worth billions.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com